Seven drugs endorsed by Scottish Medicines Consortium
Seroquel (quetiapine) and Zyprexa IM (intramuscular olanzapine) were among seven medicines to be endorsed by the Scottish
Medicines Consortium this month.
Seroquel is approved for use for manic episodes associated with bipolar
disorder and the new formulation of Zyprexa will be accepted for use
in patients with schizophrenia who have disturbed or manic behaviour
and for whom oral therapy is not appropriate.
Other recommendations include Enbrel (etanercept) for psoriatic arthritis,
Seretide (salmeterol xinafoate/fluticasone) for asthma in children aged
four to 12 years, Decapeptyl SR 11.25mg (triptorelin acetate) for advanced
prostate cancer and Movicol Paediatric Plain (macrogol) as an alternative
to Movicol-Half to treat child constipation.
Xalatan (latanoprost) is recommended for restricted use. It is accepted
for treatment of raised intraocular pressure in patients with ocular
hypertension or open-angle glaucoma for whom beta-blockers are not appropriate.
Products that did not fare so well include Bextra (valdecoxib), which
failed to be endorsed for primary dysmenorrhoea, Remicade (infliximab)
for ankylosing spondylitis, Emtriva (emtricitabine) for HIV-1 infection
and Aldurazyme (laronidase) for mucopolysaccharidosis. |
The
Pharmaceutical Journal
Acrobat
Reader